NCT03535363View on ClinicalTrials.gov

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 26, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
NSCLCNon-small Cell Lung Cancer
Interventions
DRUG

Osimertinib

Drug: Osimertinib 80mg or 40mg

Trial Locations (2)

33176

Maimi Cancer Institute - Baptist Health South Florida, Miami

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT03535363 - Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC | Biotech Hunter | Biotech Hunter